Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of “Moderate Buy” by Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $12.9550.

A number of research analysts recently weighed in on the stock. Wedbush decreased their price target on shares of Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th.

Voyager Therapeutics Stock Down 7.1%

VYGR stock opened at $4.95 on Monday. The firm has a market cap of $274.58 million, a P/E ratio of -2.68 and a beta of 0.95. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $8.27. The company’s 50-day simple moving average is $4.17 and its 200-day simple moving average is $3.55.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The company had revenue of $5.20 million during the quarter, compared to analysts’ expectations of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. On average, analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares of the company’s stock, valued at $591,926.52. This trade represents a 5.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.53% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VYGR. CWM LLC lifted its stake in Voyager Therapeutics by 856.3% in the 1st quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after purchasing an additional 9,376 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $36,000. R Squared Ltd acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $48,000. Los Angeles Capital Management LLC acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $50,000. Finally, Privium Fund Management B.V. acquired a new stake in shares of Voyager Therapeutics during the 1st quarter worth approximately $73,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.